Limited Submission Opportunities
(Applications through LSO office)
- Internal deadline: May 30, 2022
Mallinckrodt Foundation Grant Program
This program aims to support early stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis or treatment of disease.
- Extended deadline: July 22, 2022
Breast Cancer Alliance Young Investigator Grants
This program aims to fund clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers.
Intramural Funding Opportunities
- Deadline: May 27, 2022
UCSF School of Medicine Bridge Funding Program
The Bridge Funding Program provides up to 12 months of support for full-time faculty members with independent research programs, who are experiencing a temporary loss of significant funding. The program is intended to support applicants who face a funding gap between two extramural research grants (usually R01 or equivalent).
- Deadline: May 31, 2022 [Updated RFA]
HDFCCC Molecular Oncology Program "Bridging the Gap" RFA
The Molecular Oncology Program is requesting applications from any HDFCCC member (Full or Associate) for the “Bridging the Gap” Award for graduate students. Graduate students of HDFCCC faculty will apply to receive funding to support a PhD student in their 3rd or later year who is working on a cancer research project that involves collaboration with a clinical scientist.
- Deadline: July 1, 2022
HDFCCC Junior Cancer Researcher RFA
Thanks to a generous donation, the Cancer Center is requesting applications from junior researchers who have an interest in working on high-risk high-reward projects in cancer. The donor intends the funding for individuals who want to apply novel approaches to solve major cancer-specific challenges, especially those with potential clinical impact.
- Deadline: May 26, 2022
NCCN Quality of Care Initiative to Improve the Treatment of Advanced or Metastatic Bladder Cancer Patients
National Comprehensive Cancer Network (NCCN) is pleased to announce a collaboration with Pfizer Global Medical Grants (GMG) and EMD Serono to offer a new grant opportunity to support Quality Improvement projects that will advance the quality of care, including guideline concordant care, and best practices around treatment for patients with Metastatic or Advanced Bladder Cancers.
- Deadline: June 27, 2022
NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with SCLC
This opportunity is seeking Letters of Intent (LOIs), and ultimately proposals, to improve the quality of care, including the delivery of guideline concordant care, and additional innovations in the care delivery for patients with limited and extensive stage Small Cell Lung Cancer (LS-SCLC and ES-SCLC).
If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
- NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
To view NCI funding opportunities, search here